MENTAX-TC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MENTAX-TC (MENTAX-TC).
MENTAX-TC (butenafine hydrochloride) is a benzylamine antifungal agent that inhibits the synthesis of ergosterol, a critical component of fungal cell membranes, by inhibiting the enzyme squalene epoxidase. This leads to accumulation of squalene and disruption of membrane integrity, resulting in fungal cell death.
| Metabolism | Butenafine is primarily metabolized via oxidation and N-dealkylation pathways, involving cytochrome P450 enzymes, though specific isoforms have not been fully characterized. Following topical application, systemic absorption is minimal (<5%), and absorbed drug undergoes hepatic metabolism. |
| Excretion | Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine, ~60% in feces as metabolites, <1% in bile as unchanged drug. |
| Half-life | Terminal elimination half-life is approximately 20 hours (range 16-24 hours), allowing once-daily dosing. |
| Protein binding | >99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent volume of distribution is approximately 2.0 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical bioavailability is negligible (<5%) due to minimal percutaneous absorption; systemic exposure after topical application is very low. |
| Onset of Action | Topical: Clinical improvement noted within 2-3 days of twice-daily application. |
| Duration of Action | After topical application, therapeutic effect persists for 24 hours, supporting once-daily dosing regimen. |
| Molecular Weight | 329.4 |
Apply a thin layer to affected area once daily for 2-4 weeks.
| Dosage form | CREAM |
| Renal impairment | No adjustment required for renal impairment. |
| Liver impairment | No adjustment required for hepatic impairment. |
| Pediatric use | Children ≥12 years: Same as adult. Children <12 years: Not recommended. |
| Geriatric use | Same as adult dosing. |
| 1st trimester | No adequate studies in pregnant women. Use only if potential benefit justifies risk. |
| 2nd trimester | No adequate studies in pregnant women. Use only if potential benefit justifies risk. |
| 3rd trimester | No adequate studies in pregnant women. Use only if potential benefit justifies risk. |
Clinical note
Comprehensive clinical and safety monograph for MENTAX-TC (MENTAX-TC).
| Placental transfer | Unknown; likely minimal due to high molecular weight and topical application. |
| Breastfeeding | Excretion in milk unknown. Use caution; consider risk/benefit. |
| Lactation Rating | L3 (Moderately Safe) |
■ FDA Black Box Warning
None
| Serious Effects |
Known hypersensitivity to butenafine or any component
| Precautions | For external use only; not for ophthalmic, oral, or intravaginal use, Avoid contact with eyes and mucous membranes, Discontinue if irritation or sensitization occurs, Use caution in patients with known hypersensitivity to allylamine antifungal agents |
| Food/Dietary | No clinically significant food interactions. Avoid excessive alcohol consumption as it may exacerbate liver enzyme elevations (rare). |
| Clinical Pearls |
Loading safety data…
| Teratogenic Risk | Insufficient human data; animal studies not available. Risk cannot be excluded. Avoid in first trimester unless benefit outweighs risk. |
| Fetal Monitoring | Monitor for local adverse effects; no specific fetal monitoring required. |
| Fertility Effects | No known effects on fertility. |
| MENTAX-TC (butenafine hydrochloride 1% cream) is a topical antifungal of the benzylamine class. It is fungicidal against dermatophytes and fungistatic against Candida. For tinea pedis, apply once daily for 4 weeks; for tinea cruris and corporis, once daily for 2 weeks. It requires a prescription as a compounding agent. Avoid occlusive dressings. |
| Patient Advice | Apply to affected area and surrounding skin once daily for prescribed duration. · Wash hands after application unless treating hands. · Do not cover with bandage or wrap unless directed. · Avoid contact with eyes, nose, mouth, or open wounds. · Notify clinician if condition persists after 4 weeks or worsens. · Complete full course even if symptoms improve to prevent recurrence. |